Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma

Overview of attention for article published in Frontiers in oncology, August 2023

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter: 1 X user

Readers on

mendeley: 4 Mendeley

Summary X

So far, Altmetric has seen 1 X post from an account with 34 followers.

Corrigendum: Optimizing the use of lenvatinib in combination with pembrolizumab in patients with advanced endometrial carcinoma https://t.co/U4okEPJ5WH

24 Aug 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.